Tear Proteome Revealed Association of S100A Family Proteins and Mesothelin with Thrombosis in Elderly Patients with Retinal Vein Occlusion.
S100A protein
inflammation
mesothelin
retinal hemostasis
retinal vein occlusion
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
24 Nov 2022
24 Nov 2022
Historique:
received:
24
09
2022
revised:
03
11
2022
accepted:
21
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Tear samples collected from patients with central retinal vein occlusion (CRVO; n = 28) and healthy volunteers (n = 29) were analyzed using a proteomic label-free absolute quantitative approach. A large proportion (458 proteins with a frequency > 0.6) of tear proteomes was found to be shared between the study groups. Comparative proteomic analysis revealed 29 proteins (p < 0.05) significantly differed between CRVO patients and the control group. Among them, S100A6 (log (2) FC = 1.11, p < 0.001), S100A8 (log (2) FC = 2.45, p < 0.001), S100A9 (log2 (FC) = 2.08, p < 0.001), and mesothelin ((log2 (FC) = 0.82, p < 0.001) were the most abundantly represented upregulated proteins, and β2-microglobulin was the most downregulated protein (log2 (FC) = −2.13, p < 0.001). The selected up- and downregulated proteins were gathered to customize a map of CRVO-related critical protein interactions with quantitative properties. The customized map (FDR < 0.01) revealed inflammation, impairment of retinal hemostasis, and immune response as the main set of processes associated with CRVO ischemic condition. The semantic analysis displayed the prevalence of core biological processes covering dysregulation of mitochondrial organization and utilization of improperly or topologically incorrect folded proteins as a consequence of oxidative stress, and escalating of the ischemic condition caused by the local retinal hemostasis dysregulation. The most significantly different proteins (S100A6, S100A8, S100A9, MSLN, and β2-microglobulin) were applied for the ROC analysis, and their AUC varied from 0.772 to 0.952, suggesting probable association with the CRVO.
Identifiants
pubmed: 36498980
pii: ijms232314653
doi: 10.3390/ijms232314653
pmc: PMC9736253
pii:
doi:
Substances chimiques
Proteome
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 75-15-2020-913
Références
Eye (Lond). 2011 Aug;25(8):981-8
pubmed: 21546916
Invest Ophthalmol Vis Sci. 2020 Dec 1;61(14):6
pubmed: 33270842
Invest Ophthalmol Vis Sci. 2014 Apr 09;55(4):2290-6
pubmed: 24398091
PLoS Comput Biol. 2009 Jul;5(7):e1000443
pubmed: 19649320
Exp Eye Res. 2019 Feb;179:64-74
pubmed: 30321513
Oxid Med Cell Longev. 2016;2016:3565127
pubmed: 27247702
Sci Rep. 2021 May 12;11(1):10064
pubmed: 33980989
Mol Vis. 2015 May 25;21:612-20
pubmed: 26019480
Oxid Med Cell Longev. 2017;2017:9208489
pubmed: 28194256
Curr Eye Res. 1991 Jan;10(1):25-34
pubmed: 2029847
Curr Eye Res. 2012 Jan;37(1):62-7
pubmed: 21978265
Pharm Res. 2019 Jan 23;36(3):40
pubmed: 30673862
Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2133-9
pubmed: 15914634
Retina. 2012 Jan;32(1):86-91
pubmed: 21866074
PLoS One. 2013 May 21;8(5):e64619
pubmed: 23705001
J Proteome Res. 2019 Mar 1;18(3):1340-1351
pubmed: 30726097
Mol Cell Proteomics. 2010 Jun;9(6):1031-46
pubmed: 20177130
Arch Ophthalmol. 2006 May;124(5):726-32
pubmed: 16682596
J Proteomics. 2018 Jan 6;170:110-116
pubmed: 28887209
J Clin Oncol. 2016 Dec;34(34):4171-4179
pubmed: 27863199
Int J Mol Sci. 2018 Oct 25;19(11):
pubmed: 30366444
Mol Biosyst. 2013 Jun;9(6):1108-16
pubmed: 23580065
Invest Ophthalmol Vis Sci. 2002 Jan;43(1):133-9
pubmed: 11773023
Exp Eye Res. 2015 Sep;138:87-95
pubmed: 26086079
Graefes Arch Clin Exp Ophthalmol. 2001 Mar;239(3):199-207
pubmed: 11405069
PLoS One. 2016 Jun 30;11(6):e0158001
pubmed: 27362861
Eur Heart J. 2013 May;34(17):1270-8
pubmed: 23401492
J Proteome Res. 2019 Dec 6;18(12):4108-4116
pubmed: 31599596
Physiol Rev. 2014 Jul;94(3):909-50
pubmed: 24987008
Nutrients. 2021 May 18;13(5):
pubmed: 34069881
Graefes Arch Clin Exp Ophthalmol. 2010 Oct;248(10):1515-8
pubmed: 20309574
Int J Mol Sci. 2017 Apr 28;18(5):
pubmed: 28452939
Proteomes. 2022 Jan 07;10(1):
pubmed: 35076627
PLoS One. 2011;6(7):e21800
pubmed: 21789182
Vision Res. 2017 Oct;139:30-38
pubmed: 28700951
Cells. 2020 Apr 21;9(4):
pubmed: 32326243
Mol Cell Proteomics. 2019 Jul;18(7):1468-1478
pubmed: 30967486
J Biomed Sci. 2021 Jun 17;28(1):47
pubmed: 34140021
Int J Ophthalmol. 2021 Aug 18;14(8):1138-1150
pubmed: 34414076
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):815-22
pubmed: 16505012
J Spec Oper Med. 2009 Summer;9(3):59-63
pubmed: 19739477
J Clin Med. 2021 Dec 25;11(1):
pubmed: 35011849
J Biol Chem. 1999 Sep 3;274(36):25291-6
pubmed: 10464253
J Clin Med. 2020 Sep 19;9(9):
pubmed: 32961662
Exp Eye Res. 2016 Nov;152:49-56
pubmed: 27619476
JMIR Med Inform. 2021 May 31;9(5):e28868
pubmed: 34057419
Int J Mol Med. 2021 May;47(5):
pubmed: 33760148
Invest Ophthalmol Vis Sci. 2012 Jul 31;53(8):5052-9
pubmed: 22736608
Free Radic Biol Med. 1999 Mar;26(5-6):746-61
pubmed: 10218665
Nat Commun. 2020 Jul 30;11(1):3793
pubmed: 32732981
Graefes Arch Clin Exp Ophthalmol. 2021 Nov;259(11):3243-3250
pubmed: 34059950
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552
pubmed: 34723319
Curr Eye Res. 2000 Jul;21(1):581-7
pubmed: 11035540
J Am Soc Nephrol. 2004 Mar;15(3):538-48
pubmed: 14978155
Front Med (Lausanne). 2022 May 25;9:873483
pubmed: 35692536
Genes (Basel). 2021 Jun 22;12(7):
pubmed: 34206500
Proteomics. 2021 Mar;21(6):e2000093
pubmed: 33452728
Eye (Lond). 2022 May 4;:
pubmed: 35508721
Curr Med Chem. 2013;20(26):3226-33
pubmed: 23745551
Invest Ophthalmol Vis Sci. 2008 Jul;49(7):2848-55
pubmed: 18344451
J Glob Health. 2019 Jun;9(1):010427
pubmed: 31131101
Ophthalmology. 2016 Mar;123(3):625-34.e1
pubmed: 26712560
Am J Ophthalmol. 2015 Aug;160(2):313-321.e19
pubmed: 25908486